Home › Macular Degeneration › Arizona › Scottsdale
Macular Degeneration clinical trials in Scottsdale, AZ
3 studies for Macular Degeneration are looking for participants at sites in and around Scottsdale (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
RecruitingPhase 2/3
- Research Network Arizona / Retina Macula Institute of Arizona, Scottsdale
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- Retina Macula Institute of Arizona, Scottsdale
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RecruitingPhase 3
- Research Network Arizona, Scottsdale
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX13 studies
- Erie, PA10 studies
- The Woodlands, TX9 studies
- Reno, NV8 studies
- Sacramento, CA8 studies
- Hagerstown, MD8 studies
- Fort Worth, TX7 studies
- Cleveland, OH7 studies
- Carmel, IN7 studies
- Houston, TX7 studies
- Salt Lake City, UT7 studies
- Austin, TX7 studies
Other studies in Scottsdale
- Breast Cancer18 studies
- Cancer (all types)18 studies
- Metastatic Cancer17 studies
- Prostate Cancer17 studies
- Colorectal Cancer16 studies
- Non-Small Cell Lung Cancer15 studies
- Pancreatic Cancer13 studies
- Melanoma10 studies
- Ulcerative Colitis8 studies
- Lung Cancer8 studies
- Liver Cancer (Hepatocellular Carcinoma)7 studies
- Alzheimer's Disease7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.